« Previous
Next »
Titles
- PEPFAR: 20 years of progress, partnership, and impact1
- Parents’ intentions to vaccinate children for COVID-19 by child age: sociodemographic factors and reasons for hesitancy1
- Part D plans generally include drugs commonly used by dual eligibles: 20221
- Part D plans generally include drugs commonly used by dual-eligible enrollees: 20231
- Patient engagement in the design and conduct of medical device clinical studies: guidance for industry, Food and Drug Administration staff, and other stakeholders1
- Payment integrity: additional coordination is needed for assessing risks in the improper payment estimation process for advance premium tax credits : report to congressional requesters1
- Pennsylvania could better ensure that nursing homes comply with federal requirements for life safety, emergency preparedness, and infection control1
- Pennsylvania implemented our prior audit recommendations for critical incidents involving Medicaid enrollees with developmental disabilities but should continue to take action to reduce unreported incidents1
- Peripheral percutaneous transluminal angioplasty (PTA) and specialty catheters: premarket notification (510(k)) submissions : guidance for industry and Food and Drug Administration staff1
- Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry1
- Policy approaches to reduce what commercial health insurers pay for hospitals’ and physicians’ services1
- Policy approaches to reduce what commercial insurers pay for hospitals’ and physicians’ services1
- Policy for monkeypox tests to address the public health emergency: guidance for laboratories, commercial manufacturers, and Food and Drug Administration staff1
- Policy for testing of alcohol (ethanol) and isopropyl alcohol for methanol: guidance for industry1
- Policy recommendations to grow EHS-CCP in states1
- Policy regarding N-acetyl-L-cysteine: guidance for industry1
- Population pharmacokinetics1
- Postmarket surveillance under section 522 of the Federal Food, Drug, and Cosmetic Act: guidance for industry and Food and Drug Administration staff1
- Pre-Launch Activities Importation Requests (PLAIR)1
- Prescription drugs: spending, use, and prices1